US Pharma MarketingThe post ResMed completes $340m Noctrix Health acquisition appeared first on Medical Device Network.
ResMed completes $340m Noctrix Health acquisition
Noctrix Health’s lead product, Nidra, targets the peroneal nerves to address the symptoms of restless leg syndrome. Noctrix Health’s lead product, Nidra, targets the peroneal nerves to address the symptoms of restless leg syndrome. 13% of Americans report having been diagnosed with restless leg syndrome, as per research by the American Academy of Sleep Medicine. Credit: Andrey_Popov / Shutterstock.com Noctrix Health has been acquired by ResMed in a $340m deal, representing the first portfolio company exit for Angelini Ventures, the VC arm of Italian multinational Angelini Industries. Angelini Ventures invested in Noctrix in 2022 as part of the company’s $40m…
Noctrix Health’s lead product, Nidra, targets the peroneal nerves to address the symptoms of restless leg syndrome.
Source: Medical Device Network